The Pharmacy Benefit Brief | January 2021

  Welcome to the Pharmacy Benefit Brief. This brief is your monthly snapshot of news from America’s prescription drug supply chain including pharmacy benefit managers, independent pharmacies, and drug manufacturers.     Set the Record Straight on Supreme Court’s PBM Decision… Despite the narrative pushed by the independent pharmacy lobby, the Court’s short opinion inΒ Rutledge...

Keep Reading

Promoting safety of patients and pharmacy staff

  PBMs recognize home delivery can provide an alternative way of safely accessing prescribed medications. To promote expanded access to home delivery, PBMs are temporarily waiving requirements for pharmacies to obtain proof-of-receipt signatures from patients, unless required by law. Because of the high transmission risk posed by the novel coronavirus (COVID-19), proof-of-receipt requirements may represent...

Keep Reading

HHS Office of Inspector General Report Shows Rebates Reduced Medicare Part D Drug Spending

(Washington, D.C.) β€” Β Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on the Health and Human Services Officer of Inspector General report (OIG) on prescription drug rebates in Medicare Part D. β€œToday’s OIG report further dispels the false narrative about PBM-negotiated rebates and confirms that rebates lead to lower...

Keep Reading

PCMA Statement on Senate Finance Committee Hearing on Drug Prices

(Washington, D.C.) β€” Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott released the following statement on the Senate Finance Committee hearing, β€œDrug Pricing in America: A Prescription for Change, Part II:” β€œWe commend the Senate Finance Committee for holding this important hearing to shed light on drug company pricing practices, and share the...

Keep Reading

PBMs use market forces to reduce drug prices

Pharmacy benefit managers force drugmakers to compete; promote the use of low-cost generic drugs and more-affordable branded options; and offer other beneficiary-friendly, cost-saving tools, write Douglas Holtz-Eakin and Patrick Hefflinger.

Keep Reading